Titre du document / Document title

Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: A randomized trial

Auteur(s) / Author(s)

OWADA Akira ⁽¹⁾ ; SUDA Shin ⁽¹⁾ ; HATA Toshihiko ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Internal Medicine, Musashino Red Cross Hospital, Tokyo, JAPON

Résumé / Abstract

PURPOSE: Lipoprotein (a) [Lp(a)] levels increase in patients with renal disease. We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function. METHODS: Thirty-three patients with chronic renal disease whose serum Lp(a) levels were ≥15 mg/dL were randomly (but not blindly) assigned to treatment with niceritrol (n = 16) or to an untreated control group (n = 17). Parameters of lipid metabolism, excretion of urinary protein, and renal function were examined for 12 months. RESULTS: Changes in urinary protein excretion, as well as Lp(a) levels, differed significantly between the two groups. The mean (± SD) change from baseline in excretion of urinary protein was 0.77 ± 1.23 g/d in the control group compared with -1.41± 2.26 g/d in the niceritrol group at 12 months (P = 0.003). Mean Lp(a) levels increased by 3 ± 10 mg/dL in the control group compared with a decrease of 10 ± 13 mg/dL in the niceritrol group at 12 months (P =0.004). The mean creatinine clearance declined by 10 ± 12 mL/min in the control group, compared with 1 ± 13 mL/min in the niceritrol group at 12 months (P =0.06). CONCLUSION: Lipid levels improved with niceritrol treatment, whereas the excretion of urinary protein decreased, perhaps slowing the rate of loss of renal function in chronic renal disease.

Revue / Journal Title

The American journal of medicine   ISSN 0002-9343   CODEN AJMEAZ 

Source / Source

2003, vol. 114, n^o5, pp. 347-353 [7 page(s) (article)] (38 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, New York, NY, ETATS-UNIS  (1946) (Revue)

Mots-clés anglais / English Keywords

Urinary system disease ; Dyslipemia ; Metabolic diseases ; Lipids ; Renal function ; Human ; Biological activity ; Proteinuria ; Treatment ; Chemotherapy ; Hyperlipemia ; Nicotinic acid derivatives ; Antilipemic agent ; Niceritrol ;

Mots-clés français / French Keywords

Appareil urinaire pathologie ; Dyslipémie ; Métabolisme pathologie ; Lipide ; Fonction rénale ; Homme ; Activité biologique ; Protéinurie ; Traitement ; Chimiothérapie ; Hyperlipémie ; Nicotinique acide dérivé ; Hypolipémiant ; Nicéritrol ;

Mots-clés espagnols / Spanish Keywords

Aparato urinario patología ; Dislipemia ; Metabolismo patología ; Lípido ; Función renal ; Hombre ; Actividad biológica ; Proteinuria ; Tratamiento ; Quimioterapia ; Hiperlipemia ; Hipolipemiante ; Niceritrol ;

Localisation / Location

INIST-CNRS, Cote INIST : 4562, 35400011798841.0010